Biomerica Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment
15 juin 2021 08h19 HE
|
Biomerica, Inc.
IBS is one of the most important gastrointestinal disorders in Mexico, with a prevalence of around 16% [1] (approximately 20 million patients)Broadens InFoods® global patent coverage with recently...
Global Irritable Bowel Syndrome (IBS) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Analysis
09 juin 2021 06h28 HE
|
Research and Markets
Dublin, June 09, 2021 (GLOBE NEWSWIRE) -- The "Irritable Bowel Syndrome (IBS) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Diagnosis (Laboratory Tests, Imaging...
Biomerica Reports 208% Increase In Q3 Fiscal 2021 Sales, Over Q3 Fiscal 2020
15 avr. 2021 10h31 HE
|
Biomerica, Inc.
Sales increase driven by first sales of COVID-19 Antigen Rapid Test in Europe after January 2021 CE Mark approval Awarded two new patents for InFoods® diagnostic guided therapy technology, including...
$423.3 Million Worldwide Irritable Bowel Syndrome with Diarrhea Industry to 2028 - Increasing Demand for Spicy Food Will Boost the Drug Market Growth in North America
22 févr. 2021 07h23 HE
|
Research and Markets
Dublin, Feb. 22, 2021 (GLOBE NEWSWIRE) -- The "Irritable Bowel Syndrome with Diarrhea Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive...
Biomerica Reports Fiscal Year End May 31, 2020 Financial Results
01 sept. 2020 08h19 HE
|
Biomerica, Inc.
Fiscal fourth quarter revenues increase 133.7% over the prior yearFiscal 2020 revenues increase 28.7% over fiscal 2019 New InFoods® patent granted for Singapore IRVINE, Calif., Sept. 01, 2020 ...
The University of Texas Health Science Center at Houston joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy (“DGT”) clinical trial
29 juin 2020 21h39 HE
|
Biomerica, Inc.
InFoods® Diagnostic-Guided Therapy is designed to identify patient-specific foods that, when removed from the diet, may alleviate an individual's IBS symptoms Approximately 45 million Americans...
Biomerica Announces $2.0 Million Investment by Palm Global Small Cap Master Fund
26 févr. 2020 16h41 HE
|
Biomerica, Inc.
IRVINE, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) (the “Company” or “Biomerica”) announced today that the Company completed a private placement of $2 million of...
Biomerica Announces Second Quarter Financial Results; Sales Up 6.4% for the Quarter
15 janv. 2020 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Jan. 15, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $1,596,408 for the three months ended November 30, 2019, compared to $1,500,791 for the...
Houston Methodist (part of Texas Medical Center) to start patient enrollment for Biomerica’s InFoods® Irritable Bowel Syndrome (IBS) diagnostic guided therapy clinical trial
07 janv. 2020 08h19 HE
|
Biomerica, Inc.
Texas Medical Center is the largest medical complex in the world with 10 million patient encounters per year and a 1,345-acre campus (50 million square feet of developed facilities)InFoods® Diagnostic...
Biomerica Announces Fiscal Year End 2019 Financial Results
30 août 2019 08h30 HE
|
Biomerica, Inc.
IRVINE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2019 were $5,200,682...